Conditions: Renal Cell Carcinoma
Keywords: Renal Cell Carcinoma Metastatic Pazopanib Previously-treated
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 57
Healthy volunteers: no

Brief summary:
This is a Phase II, non-randomized, open-label, single-arm study in patients with metastatic renal cell carcinoma who have received one prior targeted therapy with either sunitinib or bevacizumab. The planned enrollment for this study is 60 patients.

Detailed description:
All eligible patients will receive 800 mg of pazopanib orally each day continuously. Patients will be re-evaluated for treatment response after 8 weeks of daily oral pazopanib therapy. Response to therapy will be assigned using RECIST criteria (Section 6.0) Patients who have objective response or stable disease will continue treatment with evaluations every 8 weeks, until the time of tumor progression or intolerable treatment-related side effects.

Arms:
arm 1: 800 mg of pazopanib orally each day continuously

Interventions: intervention 1: Pazopanib
Intervention descriptions: intervention 1: 800 mg of pazopanib orally each day continuously

Protocol document: